We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+2.68%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
+$197M
Cap. Flow
+$227M
Cap. Flow %
16.33%
Top 10 Hldgs %
54.77%
Holding
74
New
16
Increased
17
Reduced
14
Closed
17

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$61.8M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$41.4M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$39.5M
4
PMVP icon
PMV Pharmaceuticals
PMVP
+$38.1M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$30.1M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$31.2M
2
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$26.9M
3
VERV
Verve Therapeutics
VERV
+$18.5M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$15.8M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMGA
51
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$1.66M 0.12%
+88,235
New +$1.69M
PASG icon
52
Passage Bio
PASG
$14.7M
$1.25M 0.09%
6,251
– –
GLUE icon
53
Monte Rosa Therapeutics
GLUE
$1.86B
$1.11M 0.08%
50,000
-250,000
-83% -$7.17M
KROS icon
54
Keros Therapeutics
KROS
$199M
$593K 0.04%
+15,000
New +$534K
RPTX
55
DELISTED
Repare Therapeutics
RPTX
$525K 0.04%
20,000
-310,000
-94% -$10M
NUVB.WS
56
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$177K 0.01%
66,666
– –
MREO
57
Mereo BioPharma
MREO
$49.4M
$114K 0.01%
46,984
– –
ACRS icon
58
Aclaris Therapeutics
ACRS
$744M
– –
-675,000
Closed -$11.9M
ANNX icon
59
Annexon
ANNX
$814M
– –
-159,622
Closed -$3.59M
ATXS
60
DELISTED
Astria Therapeutics
ATXS
– –
-531,667
Closed -$6.73M
CCCC icon
61
C4 Therapeutics
CCCC
$393M
– –
-112,928
Closed -$4.27M
KNSA icon
62
Kiniksa Pharmaceuticals
KNSA
$6.11B
– –
-800,000
Closed -$11.1M
MLTX icon
63
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-50,000
Closed -$518K
OBIO icon
64
Orchestra BioMed
OBIO
$231M
– –
-100,000
Closed -$1.02M
RAPT
65
CALL
DELISTED
RAPT Therapeutics
RAPT
– –
-93,750
Closed -$23.8M
RAPT
66
DELISTED
RAPT Therapeutics
RAPT
– –
-33,750
Closed -$8.58M
TNGX icon
67
Tango Therapeutics
TNGX
$4.34B
– –
-200,000
Closed -$2.28M
ARYD
68
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
– –
-200,000
Closed -$2.14M
ASLN
69
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-50,000
Closed -$6.6M
HARP
70
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-80,000
Closed -$11.1M
PRDS
71
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-123,543
Closed -$1.23M
ISEE
72
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-2,500,000
Closed -$15.8M
RACB
73
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
– –
-100,000
Closed -$1.01M
TPTX
74
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-400,000
Closed -$31.2M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2021 Portfolio in Review

As of Q3 2021, Logos Global Management held 74 positions worth $1.39B, up 17% from $1.19B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Logos Global Management deployed $227M of net new capital in Q3 2021, opening 16 new positions and adding to 17 existing holdings. Its largest new stake was IDEAYA Biosciences: 1,775,000 shares worth $45.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Kinnate Biopharma Inc. Common Stock, an estimated $26.9M trimmed.

  • Logos Global Management's largest Q3 2021 buy was IDEAYA Biosciences: 1,775,000 shares worth $45.2M.
  • Logos Global Management added most to Apellis Pharmaceuticals in Q3 2021, an estimated $61.8M increase.
  • Logos Global Management's biggest Q3 2021 reduction was Kinnate Biopharma Inc. Common Stock, cutting an estimated $26.9M.
  • Logos Global Management fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2021, selling an estimated $31.2M.
  • Logos Global Management's ten largest holdings make up 55% of its $1.39B portfolio in Q3 2021.
  • Logos Global Management opened 16 new positions and closed 17 in Q3 2021.
  • Logos Global Management's portfolio value rose 17% quarter-over-quarter to $1.39B.

Based on Logos Global Management's 13F filing for Q3 2021, filed 15 Nov 2021.